valneva laboratory 1 (photo credit: Valneva Group / )
(AOF) – Valneva, a company specializing in vaccines, announces today the sale for 103 million dollars (95 million euros) of the priority review voucher (PRV) that it obtained from the American health agency , Food and Drug Administration (FDA).
The company received this voucher in November 2023 with the marketing authorization granted to it by the FDA for its single-injection vaccine for the prevention of disease caused by the chikungunya virus in people aged 18 years and over.
Valneva will use the proceeds from the sale of PRV to finance its R&D projects, including the co-development of its Lyme disease vaccine currently in Phase 3.